ARTICLES BY ED MISETA
-
![Stem Cells (002)]( "Stem Cell Therapy Trial Offers Hope To Osteoarthritis Patients")
Stem Cell Therapy Trial Offers Hope To Osteoarthritis Patients3/17/2020Cynata Therapeutics is producing products called mesenchymal stem cells (MSCs), which have huge therapeutic potential for numerous unmet medical needs. The company’s Cymerus technology addresses many of the challenges and complexities of manufacturing stem cells at commercial scale.
-
![cell therapy (002)]( "Former Novartis CEO: Cell And Gene Therapies Will Drive Innovation")
Former Novartis CEO: Cell And Gene Therapies Will Drive Innovation12/2/2019Joe Jimenez joined Novartis as division head of Consumer Health. A few months later, he was asked to run the pharmaceutical division. Shortly after his promotion to CEO, Novartis was the first company to pursue a CAR T therapy. Today, Jimenez marvels at the innovation taking place in the industry, and believes cell and gene therapies will drive future development.
-
![supply chain 2 (002)]( "Cell & Gene Therapies Require the Right Tracking Solution")
Cell & Gene Therapies Require the Right Tracking Solution10/15/2019In cell therapy trials, the ability to track a patient’s cells is essential. When you have over 100 patients, and the cells will require multiple shipments, using a spreadsheet is not possible. “For the safety of our patient, accurate tracking is a must,” says Gerald Garrett, VP of clinical operations for MarkerTherapeutics. “We need to know exactly where the product is at any step of the way.”
-
![Abeona-Manufacturing2]( "Manufacturing Facility Will Meet Needs Of Cell & Gene Trials")
Manufacturing Facility Will Meet Needs Of Cell & Gene Trials5/14/2019Abeona Therapeutics is developing investigational gene and cell therapies for people living with serious and rare diseases. Last year, Abeona held a ribbon-cutting ceremony to celebrate the groundbreaking of a manufacturing facility that is one year later producing gene therapy material for their clinical and pre-clinical programs. As is the norm with gene therapy, Abeona uses a virus as vehicles to deliver functional copies of defective genes.
-
![Jake LaPorte_Novartis_450x300]( "Novartis Turns To Digital Technologies For Clinical Trials")
Novartis Turns To Digital Technologies For Clinical Trials11/12/2018Jake LaPorte, head of digital development for Novartis, talks about how AI, IoT, and machine learning are all being leveraged for better clinical trials.
Ed Miseta
For more than a decade, Ed Miseta served as the Chief Editor of Clinical Leader. His tenure sadly ended in July 2023 when he passed away after a two-year battle with multiple myeloma. During his time as Chief Editor, Ed interviewed hundreds of executives from sponsor companies, patients, and technology and service providers. He regularly reported on best practices and advancements in clinical trials, detailing how both small and large sponsor companies navigate the changing landscape. In addition to his writing, Ed hosted numerous Clinical Leader Live! digital events that allowed his audience to listen to and interact with experts throughout clinical trials on a host of important issues. Beyond his duties for Clinical Leader, Ed frequently moderated and spoke at many conferences and events related to clinical trials.
Ed studied Business Economics at Penn State University and earned a Master’s degree in Business Administration. He spent 10 years in banking and investments and taught economics at Penn State for 8 years before joining Clinical Leader.